Company news
Royalty Pharma Plc (NASDAQ:RPRX) news
Royalty Pharma Plc news releases on 6ix. Latest, Sep 15, 2026: Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy…
Press releases & updates
Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program
September 15, 2026
Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen
September 4, 2026
Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million
August 12, 2026
Royalty Pharma reports second quarter 2026 results
August 5, 2026
Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives
August 3, 2026
Royalty Pharma acquires royalty interest in AstraZeneca's cliramitug for up to $425 million from Neurimmune
July 23, 2026
Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune
July 22, 2026
Royalty Pharma declares third quarter 2026 dividend
July 17, 2026
Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026
July 15, 2026
Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference
June 3, 2026
Royalty Pharma : Q1 2026 Financial Results Call Transcript
May 13, 2026
Royalty Pharma to present at upcoming investor conferences
May 7, 2026
Royalty Pharma reports first quarter 2026 results
May 6, 2026
Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation
April 21, 2026
Royalty Pharma Declares Second Quarter 2026 Dividend
April 17, 2026
Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026
April 14, 2026
Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases
March 29, 2026
Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update
March 27, 2026
Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence
March 22, 2026
Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform
March 2, 2026
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
March 1, 2026
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing
March 1, 2026
Royalty Pharma to Present at TD Cowen’s 46th Annual Health Care Conference
February 26, 2026
Royalty Pharma Reports Q4 and Full Year 2025 Results
February 11, 2026
Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
January 20, 2026
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
January 11, 2026
Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
January 10, 2026
Royalty Pharma Announces Dividend Increase
January 9, 2026
Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones
December 28, 2025
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
December 15, 2025
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
December 3, 2025
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
December 3, 2025
Royalty Pharma to Present at Upcoming Investor Conferences
November 25, 2025
Royalty Pharma Reports Third Quarter 2025 Results
November 4, 2025
Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences
November 3, 2025
Royalty Pharma Declares Fourth Quarter 2025 Dividend
October 16, 2025
Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025
October 8, 2025
Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director
September 28, 2025
Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum
September 18, 2025
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation
September 10, 2025
Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market
September 9, 2025
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
September 3, 2025
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million
September 1, 2025
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes
September 1, 2025
Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million
September 1, 2025
Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million
August 24, 2025
BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million
August 24, 2025
Henry Fernandez Steps Down from Royalty Pharma's Board of Directors
August 12, 2025
Royalty Pharma Reports Second Quarter 2025 Results
August 5, 2025